Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio7.43
Quick Ratio7.43
Price-To-Earnings
Trailing P/E Ratio-1.38
Forward P/E Ratio-2.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.67 million
Price / Sales18.09
Cash FlowN/A
Price / CashN/A
Book Value$2.53 per share
Price / Book1.34
Profitability
EPS (Most Recent Fiscal Year)($2.63)
Net Income$-114,750,000.00
Net Margins-1,061.06%
Return on Equity-85.70%
Return on Assets-73.93%
Miscellaneous
Employees78
Outstanding Shares51,600,000
Market Cap$186.77
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) issued its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. The biopharmaceutical company had revenue of $1.89 million for the quarter, compared to the consensus estimate of $1.88 million. Tetraphase Pharmaceuticals had a negative net margin of 1,061.06% and a negative return on equity of 85.70%. View Tetraphase Pharmaceuticals' Earnings History.
When is Tetraphase Pharmaceuticals' next earnings date?
What price target have analysts set for TTPH?
9 brokers have issued twelve-month price targets for Tetraphase Pharmaceuticals' shares. Their predictions range from $3.00 to $11.00. On average, they anticipate Tetraphase Pharmaceuticals' stock price to reach $7.1429 in the next year. This suggests a possible upside of 110.7% from the stock's current price. View Analyst Ratings for Tetraphase Pharmaceuticals.
What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?
Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (7/7/2018)
- 2. HC Wainwright analysts commented, "and Likely Commercial Uptake in cIAI; Affirm Buy Stock Data 05/03/2018 Price $3.15 Exchange NASDAQ Price Target $6.00 52-Week High $8.75 52-Week Low $2.05 Enterprise Value (M) $45.3 Market Cap (M) $163 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 1,678,640 Short Interest (M) 3.41 Shares Outstanding (M): Figure shown is as of May 2, 2018. Balance Sheet Metrics Cash (M) $117.7 Total Debt (M) $0.0 Total Cash/Share $2.28 Book Value/Share $1.93 Cash (M): Figure shown is as of March 31, 2018. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.46) (0.79) (0.42)A 2Q (0.47) (0.83) (0.37) 3Q (0.58) (0.63) (0.31) 4Q (0.61) (0.46) (0.24) FY (2.11) (2.63) (1.32) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 2.0 1.5 1.9A 2Q 1.2 1.6 2.0 3Q 0.9 4.1 1.8 4Q 1.1 2.5 1.5 FY 5.1 9.7 7.2 10 8 6 4 2 0 MAY-17 SEP-17 JAN-18 MAY-18 20 15 10 5 0 Vol. (mil) Price Making it official." (5/4/2018)
- 3. Needham & Company LLC analysts commented, "Tetraphase reported 4Q17 financial results yesterday after market close and we spoke w/ mgmt for an update. As a reminder, the company announced last month that the IV eravacycline Phase 3 IGNITE3 trial in complicated Urinary Tract Infections (cUTI) missed the primary endpoint. We do not expect the company to continue development in cUTI, nor to pursue development of an oral formulation of the drug. IV eravacycline is under review for complicated Intra- Abdominal Infections (cIAI) in both the U.S. and E.U. We expect approval by the 8/28/18 PDUFA date in the U.S. and in 2H18 in Europe. Maintain HOLD rating, based on concerns around commercial potential for lead asset IV eravacycline." (3/7/2018)
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include AMAG Pharmaceuticals (AMAG), Eidos Therapeutics (EIDX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Cara Therapeutics (CARA), Abeona Therapeutics (ABEO), Aptinyx (APTX), ChemoCentryx (CCXI), Vectura Group (VEGPF), Kura Oncology (KURA), Dicerna Pharmaceuticals (DRNA), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL) and Viking Therapeutics (VKTX).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 59)
- Mr. Christopher Watt, Principal Financial Officer & Principal Accounting Officer (Age 53)
- Dr. Jacques Dumas Ph.D., Chief Scientific Officer (Age 52)
- Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 47)
- Mr. Larry G. Edwards, Chief Operating Officer
Has Tetraphase Pharmaceuticals been receiving favorable news coverage?
News stories about TTPH stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 43.71 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Tetraphase Pharmaceuticals?
Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $3.39.
How big of a company is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals has a market capitalization of $186.77 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe.
How can I contact Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]
MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
